197 related articles for article (PubMed ID: 34785656)
1. The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib.
Zhuo J; Lu D; Lin Z; Yang X; Yang M; Wang J; Tao Y; Wen X; Li H; Lian Z; Cen B; Dong S; Wei X; Xie H; Zheng S; Shen Y; Xu X
Cell Death Dis; 2021 Nov; 12(12):1084. PubMed ID: 34785656
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
3. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.
Dai Z; Wang X; Peng R; Zhang B; Han Q; Lin J; Wang J; Lin J; Jiang M; Liu H; Lee TH; Lu KP; Zheng M
Cancer Lett; 2022 Jan; 524():161-171. PubMed ID: 34687791
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression.
Xu J; Huang F; Yao Z; Jia C; Xiong Z; Liang H; Lin N; Deng M
Cell Commun Signal; 2019 Jul; 17(1):85. PubMed ID: 31349793
[TBL] [Abstract][Full Text] [Related]
6. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
[TBL] [Abstract][Full Text] [Related]
7. Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro.
Dituri F; Scialpi R; Schmidt TA; Frusciante M; Mancarella S; Lupo LG; Villa E; Giannelli G
Cell Death Dis; 2020 Nov; 11(11):984. PubMed ID: 33199679
[TBL] [Abstract][Full Text] [Related]
8. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
Wu LW; Zhou DM; Zhang ZY; Zhang JK; Zhu HJ; Lin NM; Zhang C
Biochem Biophys Res Commun; 2019 May; 512(4):852-858. PubMed ID: 30929918
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
Parikh ND; Singal AG; Hutton DW
Cancer; 2017 Oct; 123(19):3725-3731. PubMed ID: 28662266
[TBL] [Abstract][Full Text] [Related]
10. CHOP regulated by METTL14-m6A affects cell cycle arrest and regorafenib sensitivity in HCC cells.
Pan Y; You B; Zhao X; Zhang S; Li W
BMC Cancer; 2024 Apr; 24(1):525. PubMed ID: 38664644
[TBL] [Abstract][Full Text] [Related]
11. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
Liu S; Du Y; Ma H; Liang Q; Zhu X; Tian J
Cancer Lett; 2019 Jul; 453():74-83. PubMed ID: 30928380
[TBL] [Abstract][Full Text] [Related]
12. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib as treatment for patients with advanced hepatocellular cancer.
Thillai K; Srikandarajah K; Ross P
Future Oncol; 2017 Oct; 13(25):2223-2232. PubMed ID: 28766967
[TBL] [Abstract][Full Text] [Related]
14. Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma.
Yukimoto A; Hirooka M; Hiraoka A; Michitaka K; Ochi H; Joko K; Imai Y; Watanabe T; Koizumi Y; Yoshida O; Abe M; Hiasa Y
Jpn J Clin Oncol; 2019 Jan; 49(1):42-47. PubMed ID: 30380075
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):611-617. PubMed ID: 29040994
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment.
Kim K; Jha R; Prins PA; Wang H; Chacha M; Hartley ML; He AR
Cancer Chemother Pharmacol; 2017 Nov; 80(5):945-954. PubMed ID: 28932966
[TBL] [Abstract][Full Text] [Related]
17. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Rimassa L; Pressiani T; Personeni N; Santoro A
Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.
Lee CH; Lee YB; Kim MA; Jang H; Oh H; Kim SW; Cho EJ; Lee KH; Lee JH; Yu SJ; Yoon JH; Kim TY; Kim YJ
Clin Mol Hepatol; 2020 Jul; 26(3):328-339. PubMed ID: 32460459
[TBL] [Abstract][Full Text] [Related]
20. Sirt3 promotes hepatocellular carcinoma cells sensitivity to regorafenib through the acceleration of mitochondrial dysfunction.
Wang R; Liu Y; Mi X; Chen Q; Jiang P; Hou J; Lin Y; Li S; Ji B; Fang Y
Arch Biochem Biophys; 2020 Aug; 689():108415. PubMed ID: 32562663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]